All Updates

All Updates

icon
Filter
Funding
Entact Bio raises USD 81 million in a Series A funding; launches from stealth
Precision Medicine
Dec 6, 2022
This week:
Product updates
Meta introduces Meta Credits digital currency for Horizon Worlds
Metaverse Platforms
Today
Product updates
Liquid AI launches STAR framework for AI model architecture optimization
Foundation Models
Today
Funding
9fin raises USD 50 million in Series B funding to expand US operations
Capital Markets Tech
Yesterday
Partnerships
Shastic partners with MeridianLink to provide AI workflow automation for financial institutions
Workflow Automation Platforms
Yesterday
Funding
KisoJi Biotechnology raises CAD 41 million to develop oncology candidate
AI Drug Discovery
Yesterday
M&A
Deel acquires UK money transfer startup Atlantic Money for undisclosed sum
Remote Work Infrastructure
Yesterday
Funding
Acorai raises EUR 4.2 million in funding to advance clinical studies
Next-gen Medical Devices
Yesterday
Product updates
Bosch announces Light Drive, an AR solution for all-day smart glasses
Extended Reality
Yesterday
Partnerships
Product updates
Vuzix expands OSHA collaboration; launches upgraded M400 AR smart glasses
Extended Reality
Yesterday
Product updates
StrikerVR launches pre-orders for consumer-facing Mavrik haptic VR gun
Extended Reality
Yesterday
Precision Medicine

Precision Medicine

Dec 6, 2022

Entact Bio raises USD 81 million in a Series A funding; launches from stealth

Funding

  • Precision medicine drug developer Entact Bio has launched from stealth and raised USD 81 million in a Series A funding round co-led by Qiming Venture Partners USA and venBio Partners, with participation from new and existing investors. 

  • The new funds will be used toward advancing its proprietary platform, Encompass, to develop enhancement-targeting chimeric molecules that enhance the function of proteins.

  • Entact Bio discovers and develops drugs targeting proteins called deubiquitinases that enhance their function and restore cells’ health to treat certain cancers, inflammatory diseases, and rare genetic disorders associated with haploinsufficiency (where patients do not have enough of a protein in their cells to combat a disease). The Encompass platform combines biological, chemical, and computational tools to identify targets to treat complex diseases.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.